Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B

By Hayashi Hidetoshi  

Breast Cancer, Vol. 20, Iss. 2, 2013-04 ,pp. : 131-136

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of Capecitabine in Combination With Thalidomide in Patients With Metastatic Breast Cancer

By Burris Howard A.   Jones Suzanne F.   Shipley Dianna   Meluch Anthony A.   Greco F. Anthony   Barton John H.   Yardley Denise A.   Hainsworth John D.  

Cancer Investigation, Vol. 28, Iss. 4, 2010-04 ,pp. : 408-412

Informa Healthcare

Access to resources Recommend Favorite

Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer

By Goto Ayumu   Yamada Yasuhide   Hosokawa Ayumu   Ura Takashi   Arai Tatsuhiro   Hamaguchi Tetsuya   Muro Kei   Shimada Yasuhiro   Shirao Kuniaki  

International Journal of Clinical Oncology, Vol. 9, Iss. 5, 2004-10 ,pp. : 364-368

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer

By Albanell Joan  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 43-44

Informa Healthcare

Access to resources Recommend Favorite

A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer

By                            

Oncology Reports, Vol. 27, Iss. 3, 2012-01 ,pp. : 657-663

Spandidos Publications

Access to resources Recommend Favorite